Ro account plan
Telehealth and in-home care
At a glance
Ro is a private US telehealth company, mostly GLP-1 weight-loss programmes, with more than $3 billion in annualized revenue.
Ro is a privately held, venture-backed US telehealth company, founded as Roman in 2017, that sells GLP-1 treatments such as Wegovy and Zepbound through its Ro Body subscription service, alongside other treatments. It announced more than $3 billion in annualized revenue in November 2026, up nearly tenfold since the 2022 revamp, with a team of roughly 400 according to its CEO on a podcast. It has not raised new money from investors in years and says it can fund itself from operations. Zachariah Reitano is co-founder and CEO.
Strategic priorities
- Branded GLP-1 leadership
- Reitano says Ro always worked directly with Novo Nordisk and Eli Lilly and is now the largest provider of branded GLP-1 drugs in the United States. He says Ro integrates with both companies.
- Protecting margins on branded drugs
- Selling branded drugs has taken a toll on telehealth margins. Reitano argues Ro expects higher margins because of subscriptions and cost efficiency, and says it cut the cost of its membership plans.
- AI in patient care and support
- Reitano says AI will speed up customer service queries and personalise treatment; he also says AI was used to help more than 1% of the US population check their insurance for free.
- Celebrity-led campaigns to reduce stigma
- Ro features ambassadors including Serena Williams and Charles Barkley, and Reitano says every ambassador actually uses the product.
- Patient-funded care
- Reitano's thesis is that where patients pay directly, prices fall and volume rises; he predicts more than half of Americans on some form of GLP-1 within 10-15 years.
Latest results
In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022. On the podcast, Reitano put the move at about a $250 million to a $3 billion run rate, with headcount down from more than 600 to roughly 400. These are figures stated by the company and its CEO; no audited accounts were read.
Investments and deals
- Own infrastructure
- Ro spent four to five years building its own electronic medical records system, its own CLIA-certified lab, its own pharmacy software and its own provider network.
- Ro Body (2023)
- Subscription service launched in 2023 to help customers obtain GLP-1 treatments and navigate insurance.
- Marketing
- Digital ads, TV commercials, subway posters and influencer campaigns, plus a Super Bowl ad with Serena Williams in 2026.
- Funding history
- A $500 million raise at a $5 billion valuation in spring 2021; Ro has raised around $1 billion to date according to PitchBook.
Challenges and risks
- Margin pressure from branded drugs
- Selling branded drugs has taken a toll on telehealth companies' margins; Hims lowered its earnings guidance for the year.
- Drug makers' own direct-to-consumer sales
- Novo Nordisk and Eli Lilly are building their own direct-to-consumer businesses while also working with Ro.
- Supply shortages
- In 2024 shortages led Ro to pause advertising temporarily and to make 50,000 phone calls to pharmacies between July and August to transfer prescriptions.
- Public reaction to its marketing
- The Serena Williams Super Bowl ad ranked near the bottom of a USA Today survey of Super Bowl ads, though Reitano says it helped persuade more consumers to seek treatment.
What leadership says
“We were just really a zombie company.”
“sometimes the best time to raise money is when you don't need it.”
Where a supplier can help
- Pharmacy and fulfilment services
- Tied to supply shortages and the 50,000 pharmacy calls made to transfer prescriptions: pharmacy-network and logistics suppliers.
- AI customer-support and insurance tooling
- Tied to the priority on AI for customer service and personalisation: vendors of patient messaging and insurance-verification software.
- Marketing and creative production
- Tied to the celebrity-led campaigns and digital, TV and subway advertising: creative, media and measurement partners.
- Margin and cost-efficiency programmes
- Tied to margin pressure from branded drugs: suppliers that lower cost per patient served.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Ro?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- How GLP-1 Drugs and a Revamp Revived Ro's Business (news article with CEO interview, syndicated copy)
- Ro announced it had more than $3 billion in annualized revenue, up nearly tenfold since the company revamped its business starting in 2022.
- Ro is nine years old and privately held; it has not raised new money from investors in years, and Reitano says it can fund itself from operations and could be profitable if it chose to be.
- Before the revamp, growth plateaued at 9 percent year-on-year after a $500 million raise at a $5 billion valuation in spring 2021; Reitano: "We were just really a zombie company."
- The "re-founding" shut more than 10 product lines, dropped long-term road maps, and cut about 20 percent of the work force by June 2022.
- In 2023 Ro launched the Ro Body subscription service for GLP-1 treatments such as Wegovy and Zepbound.
- Reitano says Ro always worked directly with Novo Nordisk and Eli Lilly and is now the largest provider of branded GLP-1 drugs in the United States.
- Selling branded drugs has hurt telehealth margins (Hims lowered its guidance); Reitano expects Ro to keep higher margins thanks to subscriptions and cost efficiency.
- A Serena Williams Super Bowl ad this year drew attention and criticism; Reitano says it helped persuade more consumers to seek GLP-1 treatments.
- Invest Like the Best with Zach Reitano: The Patient Revolution (written account of the episode, BigGo Finance)
- Reitano argues the core flaw of US healthcare is that the patient is not the customer at the point of purchase; GLP-1s sold direct to consumers are his proof it can be fixed.
- He says cash-pay competition cut GLP-1 prices from roughly $1,300 to $149 per month while drugmakers made more money on volume.
- He predicts more than half of Americans will be on some form of GLP-1 within 10-15 years, versus roughly 10-15% today.
- Turnaround: after raising $500 million at a $5 billion valuation in January 2021 and growing 9% that year, Ro cut about seven VPs and 20% of staff and refounded under one brand.
- He cites revenue up from about a $250 million to a $3 billion run rate and headcount down from more than 600 to roughly 400, with roughly 100% year-over-year growth for four years.
- He says Ro built its own EMR, CLIA-certified lab, pharmacy software and provider network; it works with both Novo Nordisk and Eli Lilly.
- He defends celebrity campaigns (Serena Williams, Charles Barkley) as a way to reduce stigma around treatment.
- Digital health companies are launching programs around GLP-1s (CNBC)
- CNBC profiles Ro among digital health companies building GLP-1 programs; Ro was founded as Roman in 2017 and started with erectile dysfunction treatments.
- In 2020 Ro switched to obesity management; after Wegovy's FDA approval the following year, Reitano said patient inquiries came in by the "tens of thousands".
- The Ro Body Program offers a prescribed GLP-1, monthly doctor meetings, an educational curriculum, 24/7 messaging, nurse coaching and insurance help, for a $145 monthly fee.
- Ro has raised around $1 billion to date according to PitchBook, and was valued at about $7 billion as of early 2022.
- Reitano described GLP-1s as a "jetpack for positive behavior change" and said patients see around a 30% reduction in calorie intake.
- During shortages Ro paused advertising, refunded patients, and made 50,000 phone calls to pharmacies from July to August to transfer prescriptions; it added Zepbound after approval in November.
Questions about Ro
What does Ro do?
Ro is a US telehealth company whose main business is GLP-1 weight-loss treatments such as Wegovy and Zepbound, sold through its Ro Body subscription service.
How large is Ro?
In November 2026 Ro announced more than $3 billion in annualized revenue, up nearly tenfold since 2022.
Is Ro publicly listed?
No. Ro is privately held and has not raised new money from investors in years; the CEO would not commit to a public listing.
Who leads Ro?
Zachariah Reitano is co-founder and CEO.
How many people work at Ro?
On the podcast Reitano said the team is roughly 400, down from more than 600.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-19)